ArticleHeliyon2025
Exploring the therapeutic potential of Danggui Shaoyao San in nephrotic syndrome: Impact on skin sodium content and renal function.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to explore the mechanism of sodium transport in the skin of rats with nephrotic syndrome (NS) and the intervention effect of Danggui Shaoyao San (DSS). NS model was established by tail vein injection of adriamycin (ADR), and different doses of DSS, vascular endothelial growth factor receptor-3 (VEGFR-3) inhibitor Levatinib and diuretic amiloride were given for intervention. We analysed serum biochemical parameters, urine sodium, skin sodium and glycosaminoglycan (GAG), lymphatic vessel density, and the expression and mRNA levels of key proteins involved in lymphangiogenesis. The results showed that DSS treatment not only significantly reduced the content of sodium ions in the skin of NS rats, but also effectively alleviated the pathological damage of the kidney, improved proteinuria and promoted the excretion of sodium in urine. At the same time, Levatinib can reduce the content of sodium ions in the skin of NS rats by inhibiting lymphangiogenesis, while amiloride can improve the state of sodium retention in the body and reduce the level of sodium ions in the skin by promoting the excretion of sodium ions in the urine of NS rats. Especially important, DSS can effectively inhibit the proliferation of renal cortical lymphatic vessels, down-regulate the expression of lymphangiogenesis related proteins and mRNA, promote urinary sodium excretion, and inhibit the transport of sodium ions from kidney to skin. In summary, this study reveals that during sodium retention in NS rats, sodium ions can be further transported to the skin for storage through increased lymph in the kidney, and DSS can inhibit renal lymphangiogenesis, promote urinary sodium excretion, and reduce the content of sodium ions in the skin, which provides a novel and potential strategy for the treatment of NS edema.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.